ANI Pharmaceuticals Management
Management criteria checks 3/4
ANI Pharmaceuticals' CEO is Nikhil Lalwani, appointed in Sep 2020, has a tenure of 5.33 years. total yearly compensation is $8.86M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 1.97% of the company’s shares, worth $31.86M. The average tenure of the management team and the board of directors is 4.2 years and 5.4 years respectively.
Key information
Nikhil Lalwani
Chief executive officer
US$8.9m
Total compensation
| CEO salary percentage | 8.97% |
| CEO tenure | 5.3yrs |
| CEO ownership | 2.0% |
| Management average tenure | 4.2yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
ANI Pharmaceuticals: Strong Buy On Rare Disease Growth, Record Of Beating Estimates
Oct 28ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 10
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Jun 21We Think Shareholders Will Probably Be Generous With ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Compensation
May 16ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth
Mar 28Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Feb 25ANI Pharmaceuticals: More Than Just A Generics Company
Feb 11ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Prospects Need A Boost To Lift Shares
Dec 18Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly
Nov 09ANI Pharmaceuticals Is Acting Like It Is Being Acquired
Nov 02ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market
Oct 11
Purified Cortrophin Gel And Strategic Acquisitions Propel Robust Revenue Surge In Rare Disease Sector
Accelerating demand for their lead Rare Disease asset and growth in generics, along with expanding sales efforts, are expected to significantly boost revenues.There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues
Sep 10ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem
Aug 14Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Aug 08ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
Aug 02Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price
Jun 10ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
Jun 10These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well
Feb 17Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings
Nov 15Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Sep 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | US$34m |
| Jun 30 2025 | n/a | n/a | -US$13m |
| Mar 31 2025 | n/a | n/a | -US$22m |
| Dec 31 2024 | US$9m | US$795k | -US$20m |
| Sep 30 2024 | n/a | n/a | -US$9m |
| Jun 30 2024 | n/a | n/a | US$24m |
| Mar 31 2024 | n/a | n/a | US$31m |
| Dec 31 2023 | US$8m | US$764k | US$15m |
| Sep 30 2023 | n/a | n/a | US$10m |
| Jun 30 2023 | n/a | n/a | -US$8m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$5m | US$737k | -US$50m |
| Sep 30 2022 | n/a | n/a | -US$69m |
| Jun 30 2022 | n/a | n/a | -US$65m |
| Mar 31 2022 | n/a | n/a | -US$63m |
| Dec 31 2021 | US$7m | US$715k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$22m |
| Jun 30 2021 | n/a | n/a | -US$17m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$4m | US$199k | -US$23m |
Compensation vs Market: Nikhil's total compensation ($USD8.86M) is above average for companies of similar size in the US market ($USD5.34M).
Compensation vs Earnings: Nikhil's compensation has been consistent with company performance over the past year.
CEO
Nikhil Lalwani (47 yo)
Mr. Nikhil Lalwani is President, CEO & Director of ANI Pharmaceuticals, Inc. from September 08, 2020. Mr. Lalwani joined the ANI Pharmaceuticals, Inc. on September 08, 2020. Mr. Lalwani served as a Directo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.3yrs | US$8.86m | 1.97% $ 31.9m | |
| Senior VP of Finance & CFO | 9.7yrs | US$2.85m | 0.87% $ 14.0m | |
| Senior VP | 3.5yrs | US$2.02m | 0.36% $ 5.8m | |
| Senior Vp & Head of Rare Disease | 4.9yrs | US$2.42m | 0.51% $ 8.3m | |
| Senior Vice President of Generics | 4.9yrs | US$2.11m | 0.40% $ 6.5m | |
| Head of R&D | 4.2yrs | no data | 0.31% $ 5.1m | |
| Chief Compliance Officer & Head of Legal of Rare Disease | 3.9yrs | no data | no data | |
| Senior Vice President of Corporate Development & Strategy | 4.2yrs | US$1.90m | 1.11% $ 18.0m | |
| Senior VP & Chief Human Resources Officer | 3.3yrs | no data | 0.28% $ 4.5m | |
| Chief Medical Officer | 3.9yrs | no data | no data | |
| Senior VP & Head of Established Brands | 4.2yrs | no data | 0.20% $ 3.2m |
Experienced Management: ANIP's management team is considered experienced (4.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.3yrs | US$8.86m | 1.97% $ 31.9m | |
| Head of R&D | 4.2yrs | no data | 0.31% $ 5.1m | |
| Independent Chairman | 7.7yrs | US$373.89k | 0.28% $ 4.5m | |
| Independent Director | 5.4yrs | US$351.39k | 0.11% $ 1.8m | |
| Independent Director | 7.7yrs | US$363.89k | 0.17% $ 2.8m | |
| Independent Director | 5.4yrs | US$353.89k | 0.11% $ 1.8m | |
| Independent Director | 3.8yrs | US$351.59k | 0.12% $ 1.9m | |
| Independent Director | 2.4yrs | US$349.60k | 0.033% $ 531.9k |
Experienced Board: ANIP's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/07 16:14 |
| End of Day Share Price | 2026/01/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ANI Pharmaceuticals, Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Dewey Steadman | Canaccord Genuity |
| Timothy Chiang | Capital One Securities, Inc. |